Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$120.88MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael G. Raab
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 489
- Beta
- 0.69
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.01
Financials
Revenue
$120.88M+187.8%Net Income
$-16.72MEBITDA
$-10.13MFree Cash Flow
$-6.41MEPS (diluted)
$-0.07Shares Outstanding (diluted)
248.07M+452.1%Operating Expenses
$127.54MCash & Debt
$281.83MRevenue by Segment (annual)
$657.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $407.32M | $-61.60M | $-0.26 |
| 2024 | $333.62M | $-39.14M | $-0.17 |
| 2023 | $124.46M | $-66.07M | $-0.30 |
| 2022 | $52.16M | $-67.21M | $-0.42 |
| 2021 | $10.10M | $-158.16M | $-1.52 |
| 2020 | $7.57M | $-94.31M | $-1.05 |
| 2019 | $5.28M | $-94.94M | $-1.47 |
| 2018 | $2.61M | $-91.30M | $-1.62 |
| 2017 | $42.00M | $-64.34M | $-1.36 |
| 2016 | $24.03M | $-112.39M | $-2.80 |
| 2015 | $24.03M | $-29.62M | $-1.29 |
| 2014 | $31.62M | $-3.21M | $-0.17 |
| 2013 | $28.93M | $-6.56M | $-0.49 |
| 2012 | $5.41M | $-9.79M | $-0.73 |
Valuation
ARDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-53.85%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·1d ago·Negative
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes
View source ↗ - Newsnewsfilecorp.com·5d ago·Positive
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX) Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NYSE: ARDX) breached their fiduciary duties owed to the Company and its shareholders.
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year
View source ↗ - Newsbusinesswire.com·15d ago·Neutral
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX LOS ANGELES--(BUSINESS WIRE)---- $ARDX--Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDX.
View source ↗ - Newsmarketbeat.com·15d ago·Negative
Ardelyx Targets $500M Revenue This Year, Profitability by 2027 Ardelyx NASDAQ: ARDX expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event.
View source ↗ - Newsbusinesswire.com·16d ago·Negative
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ARDX--ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Ardelyx to Participate in Upcoming Investor Conferences WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $-0.01 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.07 vs $-0.07miss
- Thu, Apr 30$-0.15 vs $-0.13miss
- Thu, Feb 19$0.02 vs $0.02beat
- Thu, Oct 30$-0.00 vs $-0.06beat
- Mon, Aug 4$-0.08 vs $-0.13beat
- Thu, May 1$-0.17 vs $-0.10miss
Estimates and results for ARDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARDX officers and directors.
- Bought
- $1.9m
- Sold
- $3.4m
1 trade
65 trades
- Hohenleitner Susansold
- Reilly Joseph Jamessold
- Reilly Joseph Jamessold
- Bishop John Esold
- Bishop John Esold
- Brady James Parkersold
- Brady James Parkersold
- Foster Eric Duanesold
34 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.